Inventiva's Temporary Trading Halt Announcement
Inventiva, a clinical-stage biopharmaceutical company specializing in oral therapies for metabolic dysfunction-associated steatohepatitis (MASH), has announced a temporary halt on trading its ordinary shares on Euronext Paris. This decision was made at the Company's request and took effect at the market's opening.
Reason Behind the Trading Halt
The halt comes amid Inventiva's ongoing public offering in the United States. The Company seeks to facilitate the confirmation of allocations to investors prior to announcing the pricing of this public offering. The new American Depositary Shares (ADSs) being offered represent new ordinary shares of the Company, each with a nominal value of €0.01.
Resumption of Trading
Snippets of information suggest that trading on Euronext Paris is set to resume later in the day. The anticipated reopening is expected to coincide with the start of trading on the Nasdaq Global Market, where Inventiva's shares will be available under the ticker symbol "IVA." The Company is keen on keeping its investors informed as soon as there's new communication from their end.
About Inventiva
Inventiva is engaged in significant research and development activities tailored towards providing innovative therapeutic solutions for patients suffering from MASH. The Company is currently in the process of evaluating lanifibranor, a promising novel pan-PPAR agonist, in the pivotal Phase 3 NATiV3 clinical trial. This trial targets adult patients affected by MASH, which is characterized as a progressive liver disease.
Company Overview and Investor Communication
Having its ordinary shares listed on Euronext Paris under ticker IVA and on the Nasdaq under the same symbol, Inventiva remains dedicated to its role as a public company. They are committed to transparency with their investors while navigating the unique challenges of the biopharmaceutical environment.
Contact Information
For further inquiries regarding Inventiva, the following contacts have been provided:
Inventiva:
Pascaline Clerc
EVP, Strategy and Corporate Affairs
media@inventivapharma.com
+1 202 499 8937
ICR Healthcare (Media Relations):
Alexis Feinberg
inventivapr@icrhealthcare.com
+1 203 939 2225
ICR Healthcare (Investor Relations):
Patricia L. Bank
patti.bank@icrhealthcare.com
+1 415 513 1284
Frequently Asked Questions
What is the reason for the trading halt at Inventiva?
The trading halt is due to a public offering in the U.S. that the Company initiated.
When is trading expected to resume?
Trading is expected to resume shortly after the Company's new announcements regarding the offering.
What are ADSs in relation to Inventiva?
The American Depositary Shares represent ordinary shares of Inventiva and are part of their public offering.
What is MASH?
MASH stands for metabolic dysfunction-associated steatohepatitis, a condition that Inventiva is focused on treating with novel therapies.
Who can I contact for more information about Inventiva?
You can reach out to Pascaline Clerc at media@inventivapharma.com or contact ICR Healthcare for investor relations inquiries.
